Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 11:40 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.
February 17, 2026 08:58 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average

Final EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment.